You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Boehringer Ingelheim
Mallinckrodt
Merck
McKinsey

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

SEVELAMER HYDROCHLORIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Sevelamer Hydrochloride patents expire, and what generic alternatives are available?

Sevelamer Hydrochloride is a drug marketed by Glenmark Pharms Ltd and is included in one NDA.

The generic ingredient in SEVELAMER HYDROCHLORIDE is sevelamer hydrochloride. There are thirty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the sevelamer hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Sevelamer Hydrochloride

A generic version of SEVELAMER HYDROCHLORIDE was approved as sevelamer hydrochloride by GLENMARK PHARMS LTD on February 8th, 2019.

  Start Trial

Drug patent expirations by year for SEVELAMER HYDROCHLORIDE
Recent Clinical Trials for SEVELAMER HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shanghai Alebund Pharmaceuticals LimitedPhase 2
Akebia TherapeuticsPhase 1
Shandong Weigao Panion Pharmaceutical Co. Ltd.Phase 3

See all SEVELAMER HYDROCHLORIDE clinical trials

Pharmacology for SEVELAMER HYDROCHLORIDE
Paragraph IV (Patent) Challenges for SEVELAMER HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
RENAGEL TABLET;ORAL sevelamer hydrochloride 021179 2008-05-22

US Patents and Regulatory Information for SEVELAMER HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Pharms Ltd SEVELAMER HYDROCHLORIDE sevelamer hydrochloride TABLET;ORAL 204724-001 Feb 8, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Glenmark Pharms Ltd SEVELAMER HYDROCHLORIDE sevelamer hydrochloride TABLET;ORAL 204724-002 Feb 8, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKesson
Mallinckrodt
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.